5.46 - 5.64
4.95 - 8.28
2.0K / 2.4K (Avg.)
-282.00 | -0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.49%
Negative revenue growth while HUH1V.HE stands at 2.71%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-7.01%
Negative gross profit growth while HUH1V.HE is at 0.42%. Joel Greenblatt would examine cost competitiveness or demand decline.
-11.66%
Negative EBIT growth while HUH1V.HE is at 42.65%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-11.66%
Negative operating income growth while HUH1V.HE is at 42.65%. Joel Greenblatt would press for urgent turnaround measures.
10.43%
Net income growth under 50% of HUH1V.HE's 52.96%. Michael Burry would suspect the firm is falling well behind a key competitor.
10.00%
EPS growth under 50% of HUH1V.HE's 53.45%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
10.00%
Diluted EPS growth under 50% of HUH1V.HE's 53.45%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.24%
Share change of 0.24% while HUH1V.HE is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
0.39%
Diluted share change of 0.39% while HUH1V.HE is zero. Bruce Berkowitz might see a minor difference that could widen over time.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
2359.26%
OCF growth above 1.5x HUH1V.HE's 81.70%. David Dodd would confirm a clear edge in underlying cash generation.
125.27%
FCF growth 1.25-1.5x HUH1V.HE's 101.01%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
-14.44%
Negative 10Y revenue/share CAGR while HUH1V.HE stands at 94.98%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
35.92%
5Y revenue/share CAGR at 50-75% of HUH1V.HE's 60.47%. Martin Whitman would worry about a lagging mid-term growth trajectory.
32.32%
3Y revenue/share CAGR at 75-90% of HUH1V.HE's 37.81%. Bill Ackman would expect new product strategies to close the gap.
37.33%
10Y OCF/share CAGR above 1.5x HUH1V.HE's 16.28%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-1.14%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
51.60%
Positive 3Y OCF/share CAGR while HUH1V.HE is negative. John Neff might see a big short-term edge in operational efficiency.
932.84%
Net income/share CAGR above 1.5x HUH1V.HE's 178.45% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
200.46%
5Y net income/share CAGR above 1.5x HUH1V.HE's 103.29%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
261.54%
3Y net income/share CAGR above 1.5x HUH1V.HE's 114.74%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
68.01%
10Y equity/share CAGR at 50-75% of HUH1V.HE's 125.49%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
77.29%
5Y equity/share CAGR is in line with HUH1V.HE's 73.73%. Walter Schloss would see parallel mid-term profitability and retention policies.
51.46%
3Y equity/share CAGR 1.25-1.5x HUH1V.HE's 46.54%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.48%
Inventory growth well above HUH1V.HE's 5.56%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
10.59%
Asset growth above 1.5x HUH1V.HE's 2.75%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
11.92%
Similar to HUH1V.HE's 12.19%. Walter Schloss finds parallel capital usage or profit distribution strategies.
0.61%
We have some new debt while HUH1V.HE reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-27.51%
We cut SG&A while HUH1V.HE invests at 2.16%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.